Biomarkers of HIV-1-associated neurocognitive disorders: Challenges of proteomic approaches

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


HIV-1 enters the brain shortly after infection, which may lead to neurological complications and in the most severe cases to encephalitis, dementia and death. The introduction of antiretroviral therapy reduced the incidence of the most severe conditions, nevertheless, approximately half of those infected with this virus will suffer to various degrees from HIV-1-associated neurocognitive disorders. Despite many years of research, there are no biomarkers that can objectively measure and, more importantly, predict the onset and the tempo of HIV-1-associated neurocognitive disorders. Here we review biomarker candidates of neurocognitive impairment due to HIV infection of the brain that have been proposed during the last two decades, and discuss perspectives and limitations of proteomic approaches in the search for new, more sensitive and specific biomarkers.

Original languageEnglish (US)
Pages (from-to)771-785
Number of pages15
JournalBiomarkers in Medicine
Issue number6
StatePublished - 2009


  • AIDS
  • Biomarker
  • Cerebrospinal fluid
  • Cognitive impairment
  • Dementia
  • HAD
  • HAND
  • HIV
  • Plasma
  • Proteomics

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Biomarkers of HIV-1-associated neurocognitive disorders: Challenges of proteomic approaches'. Together they form a unique fingerprint.

Cite this